Single-cell sequencing of human white adipose tissue identifies new cell states in health and obesity

Andrew D. Hildreth1,2,5, Feiyang Ma3,4,5, Yung Yu Wong1, Ryan Sun1, Matteo Pellegrini3,4 and Timothy E. O’Sullivan1,2

White adipose tissue (WAT) is an essential regulator of energy storage and systemic metabolic homeostasis. Regulatory networks consisting of immune and structural cells are necessary to maintain WAT metabolism, which can become impaired during obesity in mammals. Using single-cell transcriptomics and flow cytometry, we unveil a large-scale comprehensive cellular census of the stromal vascular fraction of healthy lean and obese human WAT. We report new subsets and developmental trajectories of adipose-resident innate lymphoid cells, dendritic cells and monocyte-derived macrophage populations that accumulate in obese WAT. Analysis of cell–cell ligand–receptor interactions and obesity-enriched signaling pathways revealed a switch from immunoregulatory mechanisms in lean WAT to inflammatory networks in obese WAT. These results provide a detailed and unbiased cellular landscape of homeostatic and inflammatory circuits in healthy human WAT.
Results

Single-cell sequencing reveals a diverse WAT immune system.

To understand the unbiased cellular composition of the SVF of healthy human WAT, we isolated single-cell suspensions of deep subcutaneous abdominal adipose tissue from three lean and three obese patients. Patients were considered ‘healthy’ if they had no history of cardiovascular or liver disease, diabetes or immunological disorders (Supplementary Table 1). Single-cell suspensions were sorted into CD45+ (hematopoietic) and CD45− (nonhematopoietic) populations for each patient sample, and then profiled using 10X Genomics Chromium droplet scRNA-seq (Fig. 1a). The resulting quality-controlled, human WAT SVF single-cell atlas included 82,577 cells that were clustered based on differential expression of marker genes and visualized using a uniform manifold approximation and projection (UMAP) plot (Fig. 1b, Extended Data Fig. 1a and Supplementary Table 2). Cluster annotation and identification were corroborated using overlapping marker genes from the Human Cell Atlas and previous scRNA-seq datasets profiling human immune lineages and parenchymal cells10–15. Clustering analysis revealed 19 distinct clusters: adipocyte precursor cells (APCs), preadipocytes (pADs), smooth muscle cells (SMCs), endothelial cells (Endos), conventional type 1 DCs (cDC1s), perivascular macrophages (PVMs), nonclassic monocytes (ncMos), B cells, naive CD4+ T cells, naive CD8+ T cells, cytotoxic CD8+ T cells, CD8− γδ T cells, regulatory T (Treg) cells, mucosa-associated invariant T cells (MAITs), mature NK (mNK) cells, and four previously uncharacterized clusters of myeloid-like cells, conventional type 2B DC-like cells (cDC2Bs), NK-like cells and non-NK ILCs (Extended Data Figs. 1a,b and 2a–c).

Identified clusters contained cells from both lean and obese WAT samples, suggesting that each identified cell type was associated with a common cell lineage rather than derived from a single patient sample (Fig. 1c). Analysis of the frequency of lean and obese patient cells in each cluster revealed an increased proportion of Endos and adipose-resident DCs, unconventional T cells, ILCs, and myeloid-like and NK-like cells in obese WAT samples. In contrast, frequency analysis suggested a decreased or unchanged proportion of pADs, circulating CD8+ and CD4+ T cell subsets, B cells and other myeloid populations (Fig. 1d,e). To interrogate these changes, we first used an independent cohort of four lean, four overweight and three obese individuals to validate all identified structural cell and conventional and innate-like T cell populations by flow cytometry (Extended Data Figs. 1c and 2d, and Supplementary Table 3). Using an additional cohort of four lean patients, we confirmed KLRB1 (CD161) expression on a defined population of MAITs and detected the presence of CD45+CD8− and CD45−γδ T cells, in addition to a rare population of Vα24–α18-positive invariant NK T (iNKT) cells that could not be resolved by our 36,601, non-B cell lymphoid lineage, scRNA-seq dataset (Extended Data Fig. 2e,f and Supplementary Table 3). Flow cytometry further supported our scRNA-seq analysis, demonstrating that WAT Endos and APCs, as well as γδ T cells, MAITs, and CD4+ and Treg cells positively correlated with increasing patient body mass index (BMI). In contrast, SMCs, pADs and CD8+ T cells had a negative correlation. Interstitial progenitor cells had no correlation with patient BMI (Fig. 1f,g, and Extended Data Figs. 1d and 2g). Although these results suggested that human obesity is associated with an accumulation of diverse nonimmune and lymphoid cell lineages consistent with tissue-resident phenotypes, how WAT-resident ILC and myeloid populations changed during obesity remained unclear. Several of the obese-enriched cell clusters (NK cell like, myeloid cell like, ILC, cDC2B like) probably represented heterogeneous populations of transcriptionally similar cell types or new cell subsets that have not been described previously, suggesting that analysis of a larger sample size from sorted subsets was necessary to confirm cell-lineage identification.

Unique WAT-resident ILC subsets accumulate in obese patients.

Previous studies from mice and humans suggest that ILCs consist of a heterogeneous family that can be classified into three distinct groups based on the expression of transcription factors, cell surface markers, and effector cytokines14. Our CD45−sorted scRNA-seq dataset suggested that CD200R1 expression could distinguish ILCs from mNK cells, similar to previous studies performed in mice and human peripheral blood mononuclear cells (PBMCs)26–27. To examine whether further cellular heterogeneity existed in human WAT ILCs, we pooled single-cell suspensions from the WAT of either seven lean or five obese patients and sorted CD45−Lin−CD7−CD200R1+ or CD45−Lin−CD7−CD200R1− populations that were subsequently analyzed using scRNA-seq (Extended Data Fig. 3a and Supplementary Table 4). Assessment of 14,849 pooled cells from both sorted populations revealed 7 distinct clusters based on differential expression of marker genes (Fig. 2a, Extended Data Fig. 3b and Supplementary Table 5). Similar to the CD45−sorted scRNA-seq dataset, mNK cells comprised a distinct cluster marked by expression of FCGR3A, FGFBP2, KLRF1 and EOMES (Fig. 2b and Extended Data Fig. 3b,c). However, we also identified the presence of two additional distinct NK cell subsets derived from CD45−Lin−CD7−CD200R1− cells that expressed lower levels of FCGR3A and KLRF1, and displayed similar cluster marker expression with previously identified NK-like cell clusters: one cluster of NK-like cells discerned by expression of IL7R, SELK and CD2 similar to previously described CD56−bright immature NK (iNK) cells in human peripheral tissues18, and a population of NK-like cells distinguished by expression of CXCRL6, KLRC1 and GZMK consistent with tissue-resident NK (trNK) cells described in the human liver19–21 (Fig. 2b and Extended Data Fig. 3b,c). Four clusters did not express the NK cell-lineage-associated genes IFN8, EOMES, KLRF1, NCAM1 or PRF1. Instead, these clusters could be distinguished from NK-lineage cells based on CD200R1 and IL7R coexpression and were derived from sorted CD45−Lin−CD7−CD200R1+ cells, but not CD45−Lin−CD7−CD200R1− cells, indicating that these clusters represented ILCs (Fig. 2a–c and Extended Data Fig. 3b–d). WAT ILC clusters were defined based on differential expression of marker genes: GATA3 and IL1R1 consistent with ILC3s described in mice and humans22–24, ZNF683 and TBX21 consistent with ILC1s described in mice25–29; CCR6, IL1R1 and IL23R consistent with ILC3s described in mice and humans30–32; and SELK and IL1R1 consistent with circulating ILC precursor cells (ILCPs) found in human blood30–32 (Fig. 2bc and Extended Data Fig. 3b,c). These results confirmed that CD200R1 could be used as a bona fide surface marker to distinguish ILCs from NK-lineage cells in human WAT. Analysis of the frequency of lean and obese patient cells in each cluster suggested an accumulation of trNK cells and ILC3s in obese WAT, with a decrease in mNK cells and ILCP-like cells, and little change in other identified subsets (Extended Data Fig. 3e).

To functionally validate the existence of identified NK cell and ILC clusters, we utilized WAT samples from 2 additional cohorts of 26 (10 lean, 9 overweight, 7 obese) and 12 (5 lean, 4 overweight, 3 obese) patients, respectively (Supplementary Table 3). Flow cytometry experiments corroborated the results from our scRNA-seq analysis, supporting the identification of three distinct IFN-γ-producing NK cell populations based on PERFORIN, CD62L, CD16, TBET and EOMES expression: TBET+EOMES−PERFORIN−CD62L−mNK cells; TBET−EOMES−PERFORIN−CD62L−trNK cells; and TBET−EOMES+PERFORIN−CD62L−trNK cells (Fig. 2d,e and Extended Data Figs. 4a,c). Comparison of WAT NK cell subsets with human PBMC-derived CD56−bright and CD56−dim NK cells suggested that, although WAT mNK cells phenotypically overlap with CD56−dim NK cells, WAT iNK and trNK cells were phenotypically distinct from CD56−dim NK cells and potentially represent unique subsets of the NK-cell lineage found in the WAT (Fig. 2e). Furthermore, mature CD200R1+ ILC populations did not express PERFORIN or...
Fig. 1 | Single-cell sequencing reveals the cellular heterogeneity of the SVF of human WAT. a, Schematic of the experimental pipeline. Human adipose tissue was isolated from healthy patients (patient information in Supplementary Table 1), dissociated into single-cell suspensions, sorted into CD45− and CD45+ populations, and analyzed using 10x Genomics Chromium droplet scRNA-seq. Cells were clustered via differential gene expression, and ligand–receptor analysis was performed to assess the interactions between cell types. b,c, UMAP plot of 82,577 human adipose cells isolated from the SVF of 3 lean and 3 obese patients. b, Annotations are derived from cluster-specific analysis (Extended Data Fig. 1). c, UMAP indicating the patient sample categorization as lean (red) or obese (blue). d,e, Boxplots showing the proportion of nonimmune (d) and immune (e) cells derived from n = 3 lean (red) and n = 3 obese (blue) patients for each cell type. The center is the median, the box limits the upper and lower quartiles, and the whiskers are 1.5× the interquartile range. f–g, Density correlation analysis of accumulating nonimmune (f) and T cell (g) subsets with patient BMI. Line of best fit and 95% CIs are shown for each plot. Each point represents an individual patient. Linear regression and two-tailed Pearson’s correlation analysis with 95% CIs were conducted. P < 0.05 was considered significant.
but not ILC2, populations (Fig. 3c). Monocle pseudotime analysis further corroborated the ILCP-like cells to ILC1 and ILC3 transition, and assessment of the frequency of lean and obese patient cells in each cell cluster revealed a shift in frequency from ILCP-like cells and ILC1s in lean samples to ILC3s in obese samples (Fig. 3d,e). Analysis of differentially expressed genes (DEGs) between the ILC1 and ILC3 fates from ILCP-like cells showed a clear bifurcation, further suggesting a developmental switch to the ILC3 fate during obesity (Extended Data Fig. 5). Ingenuity pathway analysis (IPA) implicated both IL-23 and STAT3 signaling as important mediators of the transition to the ILC3 fate, whereas IFN-α coupled with ID2 and STAT5B signaling regulated the transition to the ILC1 fate (Fig. 3f and Supplementary Table 6,7). These results suggest that a previously unidentified shared ILC1–ILC3 precursor exists in the human WAT, and that the accumulation of WAT-resident ILC3s during obesity may be due to increased ILC3 differentiation from ILCP-like cells.

**Distinct DC and macrophage subsets accumulate in obese WAT.**

To examine whether further cellular heterogeneity in human WAT myeloid cells, we pooled single-cell suspensions from the WAT of either seven lean or five obese patients and sorted CD45+Lin−CD11b+CD14+ and CD45+Lin−CD11b+CD14+HLA-DR+CD11c+ populations that were subsequently analyzed using scRNA-seq (Extended Data Fig. 6a and Supplementary Table 4). Assessment of pooled cells from both sorted populations resolved 12,824 healthy human WAT DCs, macrophages, monocytes and neutrophils that clustered into 10 distinct populations based on differential expression of marker genes (Fig. 4a,b, Extended Data Fig. 6b–d and Supplementary Table 8). Our analysis identified three populations of monocytes: nMos based on expression of FCGR3A and HES4, Mo-1s by expression of FCER1A and Mo-2s via increased expression of CSF3R, FCAR and SELL, compared with Mo-1s (Fig. 4b and Extended Data Fig. 6b–d). Using cluster annotation and cell cluster identification data from the Human Cell Atlas and other previously published datasets11,12,14,15, we created module scores to assess the identity of the Mo-1 and Mo-2 populations (Supplementary Table 9). Analysis of gene expression data and module score results suggested that Mo-1s and Mo-2s both displayed enrichment for the classic monocyte gene module, suggesting the presence of two cell states of classic monocytes (Extended Data Fig. 6e). The scRNA-seq analysis also identified a population of human WAT neutrophils based on expression of THBS1 and S100A12, which displayed enrichment for the neutrophil gene module compared with other myeloid cell clusters (Fig. 4b and Extended Data Fig. 6b,c,f). We confirmed the presence of two previously identified macrophage subsets present within the human WAT: TREM2, CD9 and LPL expressing lipid-associated macrophages (LAMs)5, LYVE1, SELENOP and...
C1Q, expressing PVMs, and an uncharacterized inflammatory macrophage (IM) population with high expression of CCL3L1, TNF and CXCL3 (Fig. 4b and Extended Data Fig. 6b,c). Furthermore, analysis of the frequency of lean and obese patient cells in each cluster revealed an accumulation of IMs, LAMs, and Mo-1 and Mo-2 cells with a decrease in PVMs, neutrophils and ncMos in obese
To confirm that CD206+CD11c+ WAT macrophages represented IMs, we harvested WAT from an additional cohort of individuals (four lean, two overweight, four obese) and profiled endogenous IL-1β and TNF production by flow cytometry (Supplementary Table 3). Although PVMs showed little endogenous production of TNF or IL-1β, both LAMs and IMs showed increased IL-1β production and a trend toward higher TNF production in obese compared with lean patients, suggesting that IM and LAM populations are subsets of proinflammatory macrophages in obese WAT (Fig. 4e and Extended Data Fig. 7c).

In contrast to our CD45+–sorted scRNA-seq dataset, DC-sorted scRNA-seq analysis identified three distinct WAT DC populations: conventional type 1 DCs (cDC1s) defined by expression of IRF8, DPP4, CADM1 and XCR1, conventional type 2 DCs subset A (cDC2A), via expression of CD1C, IRF4, IL7R and LAMP3, and conventional type 2 DCs subset B (cDC2B), by increased expression of CD1C, IRF4, FCER1A and CLEC10A, consistent with the phenotypes of DC subsets recently reported in human blood. In contrast to our CD45+–sorted scRNA-seq dataset, DC-sorted scRNA-seq analysis identified three distinct WAT DC populations: conventional type 1 DCs (cDC1s) defined by expression of IRF8, DPP4, CADM1 and XCR1, conventional type 2 DCs subset A (cDC2A), via expression of CD1C, IRF4, IL7R and LAMP3, and conventional type 2 DCs subset B (cDC2B), by increased expression of CD1C, IRF4, FCER1A and CLEC10A, consistent with the phenotypes of DC subsets recently reported in human blood. In contrast to our CD45+–sorted scRNA-seq dataset, DC-sorted scRNA-seq analysis identified three distinct WAT DC populations: conventional type 1 DCs (cDC1s) defined by expression of IRF8, DPP4, CADM1 and XCR1, conventional type 2 DCs subset A (cDC2A), via expression of CD1C, IRF4, IL7R and LAMP3, and conventional type 2 DCs subset B (cDC2B), by increased expression of CD1C, IRF4, FCER1A and CLEC10A, consistent with the phenotypes of DC subsets recently reported in human blood.
subsets by expression of CD206, CD14, FER1A and CLEC10A: cDC2Bs (CD26^–CD1C^–CD206^+CD14^+FER1A^+CLEC10A^+); cDC2As (CD26^+CD1C^+CD206^–CD14^+FER1A^+CLEC10A^–) (Fig. 4g and Extended Data Fig. 7d). Although DC subset frequencies did not change, their densities increased in obese compared with lean patients, positively correlating with increasing patient BMI (Fig. 4h,i and Extended Data Fig. 7e). Furthermore, IMs and LAMs were not present in high frequencies or densities in lean WAT, but drastically accumulated in obese WAT and positively correlated with increasing patient BMI (Fig. 4j,k and Extended Data Fig. 7f,g). Altogether, these data suggest that cDC1, cDC2B, cDC2A, LAM and IM populations accumulate in obese human WAT (Fig. 4h–k and Extended Data Fig. 7c–g).

**Classical monocytes differentiate into PVMs and IMs in WAT.**

Studies in mice have shown that recruitment of CCR2-dependent monocytes is required for adipose tissue inflammation, proinflammatory macrophage accumulation and insulin resistance. Although these studies suggest that circulating monocytes give rise to most of the IMs in obese mice, previous work has also proposed that WAT-resident macrophages are polarized to a metabolically activated proinflammatory phenotype. However, the ontogeny and upstream regulators of inflammatory macrophages in human WAT are not well understood. To test whether scRNA-seq–identified monocyte or macrophage subsets were precursors to WAT IMs and LAMs, we used RNA-velocity analysis (Fig. 5a). UMAP visualization of manually subclustered monocyte and macrophage subsets suggested that the Mo-1 population was most transcriptionally related to both the Mo-2 and the PVM populations, whereas Mo-2s appeared to be more transcriptionally similar to IMs. Projection of the velocity field arrows onto the UMAP plot showed a strong directional flow of the Mo-1 cluster to both PVM and IM fates, suggesting that human WAT macrophages are derived from the Mo-1 cell state in silico (Fig. 5a). CytoTRACE analysis indicated that both PVMs and a subset of Mo-1s were the least differentiated cell states, whereas LAMs, Mo-2s and IMs represented more highly differentiated cell types (Fig. 5b). Manually averaged principal curves incorporating both RNA-velocity vectors and CytoTRACE differentiation scores suggested distinct developmental trajectories from Mo-1s to PVMs and IMs, with Mo-2s representing an additional transition state between Mo-1s and IMs in obese cells, as well as differentiation from PVMs to LAMs (Fig. 5c). Monocle pseudotime analysis further supported the bifurcation of PVM and IM fates from Mo-1s (Fig. 5d). Analysis of the frequency of lean and obese patient cells in each cell cluster displayed a preference of Mo-1 transitioning to IMs rather than to PVMs in obese cells, suggesting a developmental shift from monocyte-derived PVMs in lean patients to polarization of Mo-1s to IMs in obese WAT (Fig. 5e). Analysis of the DEGs between PVM and IM fates showed a clear bifurcation in gene expression programs (Extended Data Fig. 8). We then assessed the potential upstream regulators of the DEGs between Mo-1s to PVMs and IMs as well as PVMs to LAMs using IPA (Fig. 5f–h and Supplementary Tables 10–13). This implicated proinflammatory cytokines (TNF, IFN-γ, IL-1β, IL-6, oncostatin M (OSM) and migration inhibition factor (MIF)) and signaling pathways (Jun-Fos) as significant mediators of the transition of Mo-1s to IMs, whereas anti-inflammatory cytokines (IL-1RA, IL-13 and IL-37) and transcription factors (NANOG, MAFB, MEF2C and GATA4) were suggested to regulate the transition to PVMs (Fig. 5g). IPA suggested that similar proinflammatory cytokines TNF, IFN-γ, IL-1β and IL-12A, and signaling pathways involving Jun-Fos, mediated the transition from PVMs to LAMs (Fig. 5h). Our analysis also suggested hypoxic signaling pathways involving hypoxia-inducible factor (HIF)-1α, aryl hydrocarbon receptor nuclear translocator (ARNT), and endothelial PAS domain protein 1 (EPAS1) may regulate the PVM-to-LAM transition. Thus, these results suggest an obese WAT microenvironment-induced shift in monocyte-derived macrophage development toward proinflammatory subsets influenced by specific proinflammatory cytokines and hypoxia.

**Ligand–receptor analysis reveals WAT interactomes.**

Given the observed changes in immune composition of obese compared with lean human WAT, we next analyzed how WAT cellular communication networks changed during obesity. To do this, we performed ligand–receptor analysis on all lean WAT cells acquired using CellPhoneDB to generate a lean WAT homeostatic interactome (Supplementary Table 14). CellPhoneDB ligand–receptor analysis revealed thousands of structural cell-to-immune as well as immune-to-immune interactions (Fig. 6a). Connectome web analysis of putative WAT-resident populations revealed structural cells, DCs, ILC subsets and PVMs as central communication hubs in the healthy lean WAT (Fig. 6b). Analysis of highly expressed interactions uncovered various uncharacterized and validated signaling pathways implicated in adipose tissue homeostasis and immuno-regulation in mice (Fig. 6c). Analysis of the lean interactome suggested that cDC2As may serve an immunoregulatory role via production of growth arrest-specific 6 (GAS6), Jagged1 (JAG1), platelet-derived growth factor (PDGF)β and AREG, interacting with APCs, pADs, Endos and SMCs. These cells could contribute to the maintenance of the WAT via interactions involving Nectin2 and inducible co-stimulator ligand (ICOSLG) with T<sub>reg</sub> populations and CD200–CD200R with ILCs. Furthermore,
cDC2As uniquely expressed the chemokines CCL17, CCL22 and CCL19, and the cytokine IL-15, which interacted with ILCs, NK cells and APCs, suggesting additional roles for cDC2As in the recruitment and maintenance of innate lymphocytes and progenitor cell types in the lean WAT. pADs expressed IL-15RA, suggesting a synergistic mechanism with cDC2A-derived IL-15 to regulate...
WAT lymphocyte populations. In contrast, PVMs probably play an important role in WAT homeostasis through interactions with structural cells involving vascular endothelial growth factor A (VEGFA), transforming growth factor (TGFβ) and PDGFC. Among ILCs, ILC3s may play similar homeostatic roles to ILC2s via ICOS and TNF receptor superfamily member 25 (TNFRSF25).

**Fig. 5 | RNA-velocity analysis uncovers a distinct monocyte state upstream of adipose IMs in obese individuals.** a, RNA-velocity analysis of WAT monocyte and macrophage clusters with velocity field projected on to the UMAP plot of human adipose myeloid cells subclustered from Fig. 4. Arrows show the local average velocity evaluated on a regular grid and indicate the extrapolated future states of cells. b, CytoTRACE scatter plot of WAT monocyte and macrophage clusters. The color indicates the level of differentiation from low (gray) to high (red). c, UMAP plot of WAT monocyte and macrophage clusters with velocity arrows and corresponding principal curves shown in bold. Principal curves indicate the manually averaged differentiation directionality projected by RNA-velocity and CytoTRACE analyses. d, Monocle analysis of the Mo-1, PVM and IM populations indicating pseudotime directionality (left) and cell type (middle): PVM (red), Mo-1 (blue), IM (red); and patient source classification as lean or obese (right): lean (red), obese (blue). e, Bar plots showing the proportion of the indicated myeloid populations derived from seven lean and five obese patients. f–h, IPA of putative upstream regulators (left) and transcription factors (right) implicated in the Mo-1-to-IM transition (f), the Mo-1-to-PVM transition (g) or the PVM-to-LAM transition (h).

**Fig. 6 | CellphoneDB analysis reveals the lean human WAT interactome.** a, Interaction heatmap plotting the total number of lean WAT-derived cell receptor (y axis) and ligand (x axis) interactions for the specified cell types. The color represents the number of interactions between cell types: higher number of interactions (red), lower number of interactions (blue). b, Connectome web analysis of lean interacting tissue-resident cell types based on expression of the ligand in at least 25% of the cell population. Vertex (colored cell node) size is proportional to the number of interactions to and from that cell, whereas the thickness of the connecting lines is proportional to the number of interactions between two nodes. c, Dot plots showing expression of ligands (left) and receptors (right) in human tissue-resident WAT cells; only ligands and receptors from cell types with detected expression (>25%) are shown. Implicated chemokines can be found in the lower panel. Color saturation indicates the strength of expression in positive cells, whereas dot size reflects the percentage of each cell cluster expressing the gene.
signaling, and trNK cells may function in maintaining DC populations in the lean adipose tissue via CSF2–CSF2R signaling. Together, these results implicate diverse structural and immune cell crosstalk in the maintenance of human WAT homeostasis, and suggest that protective anti-inflammatory mechanisms may be active within healthy lean WAT.
Fig. 7 | CellphoneDB analysis predicts a dramatic remodeling of the human WAT interactome in obesity. a, Interaction heatmap plotting the total number of lean WAT-derived cell receptor (y axis) and ligand (x axis) interactions for the specified cell types. The color represents the number of interactions between cell types: higher number of interactions (red), lower number of interactions (blue). b, Connectome web analysis of obese highly interacting cell types based on expression of the ligand in at least 25% of the cell population. Vertex (colored cell node) size is proportional to the number of interactions to and from that cell, whereas the thickness of the connecting lines is proportional to the number of interactions between two nodes. c, Dot plots showing expression of ligands (left) and receptors (right) in human WAT cells; only ligands and receptors from cell types with detected expression (>25%) are shown. Implicated chemokines can be found in the lower panel. Color saturation indicates the strength of expression in positive cells, whereas dot size reflects the percentage of each cell cluster expressing the gene.
To assess the changes that occur to the cellular communication network during obesity, we similarly performed CellPhoneDB ligand–receptor analysis on all obese WAT cells. Analysis of the cell–cell interactions indicated an increased number of overall ligand–receptor pairings in obese compared to lean cells, especially ligand–receptor interactions involving recruited circulating myeloid and macrophage subsets (Fig. 7a). Connectome web analysis revealed an enrichment of PVM, IM, cDC2B and LAM communication hubs within the obese WAT (Fig. 7b,c). Analysis of the obese interactome suggested that IMs and LAMs probably contribute to adipose tissue inflammation during obesity via TNF-α, IL-1β, IL-18, CXCL8, PDGFβ- and TNFSF13B–mediated regulation of stromal cells, DCs and circulating myeloid subsets. Interestingly, our analysis suggested that PVM populations in obesity act as major producers of the chemokines (CCL3, CCL3L1, CCL4 and CCL2) involved in the recruitment of myeloid cells. Previous studies have demonstrated that CCL2–CCR2–mediated recruitment of monocytes contributes to adipose tissue inflammation and systemic insulin resistance in mouse models of obesity, suggesting that PVMs may indirectly contribute to inflammation in humans in a similar manner. cDC2Bαs expressed MIF, IL-18, IL-1β and TNFSF9, interacting with ILCs, NK cells and myeloid cells, suggesting that DC populations may exacerbate adipose tissue inflammation and tissue fibrosis in a similar manner to proinflammatory macrophages. trNK cells paired with WAT DC populations via LIGHT (TNFSF14–TNFRSF14) interactions. As LIGHT signaling has also been shown to enhance adipose tissue macrophage-mediated inflammation, these results may suggest a role for trNK cells in human obesity-associated inflammation. Similarly, obese ILC3s appear to be mediators of adipose tissue inflammation via TNFSF13B and MIF, acting on macrophage, DC and monocyte subsets. Together, these data suggest significant inflammatory shifts within the WAT interactome during obesity, and implicate new cell types in the potentiation of human WAT inflammation during obesity (Extended Data Fig. 9a).

IPA uncovers a distinct obese-enriched WAT signalosome. To understand whether predicted interacting cell types influence transcriptional changes during obesity, we performed IPA on the DEGs between all lean and obese WAT cell populations (Supplementary Tables 15 and 16). Our analysis uncovered approximately 110 genes implicated as putative shared upstream regulators in ≥2 cell types. Analysis of highly expressed upstream regulators suggested that many of the inflammatory signals identified using CellPhoneDB served as transcriptional regulators of gene expression during obesity (Fig. 8a). A number of common upstream regulators identified by our analysis (TNF, IL-1β, IL-18, IL-6, insulin-like growth factor (IGF) 1, IFN-γ, CXCL8 and OSM) were also found to be previously associated with human systemic insulin resistance (Fig. 8a and Supplementary Data Table 17). Furthermore, our analysis suggested that many previously uncharacterized WAT-resident immune cells including IMs, cDC2As, cDC2Bs, ILC3s and trNK cells highly expressed the upstream ligands of many of these key pathways in obesity. Our analysis also found several secreted upstream regulators that have not yet been associated with human insulin resistance, but have been suggested to play a role in the development of metabolic dysfunction in mice (CSF2, leukemia inhibitory factor (LIF), bone morphogenetic protein (BMP) 4, endothelin 1, CXCL12 and TNFSF13B) (Supplementary Data Table 17). Analysis of nonsecreted upstream regulators suggested that several transcription factors (HIFI-α, cAMP response element-binding protein (CREB), MYC, CCAAT/enhancer-binding protein beta (CEBPB), forkhead box protein O1 (FOXO1) and STAT4), implicated in obesity-associated inflammation and metabolic dysfunction in mice (Supplementary Data Table 17), may also be important in regulating adipose tissue inflammation in human cells (Fig. 8b). Together, gene set enrichment analysis of the common upstream regulators suggested a number of significant pathways that were transcriptionally regulated in obese WAT cells (Fig. 8c and Supplementary Table 18). Implicated signaling mechanisms involved several JAK–STAT signaling pathways, including IL-1, IL-6, IL-12, IL-17, IFN-γ signaling, TNF signaling and hypoxia. Furthermore, many of these pathways were induced in new human WAT cell types, as shown by gene set enrichment analysis of obese trNK cells, ILC3s, cDC2Bs and IMs (Extended Data Fig. 9b–e). Combined, these data suggest that a complex mixture of inflammatory pathways produced by macrophages, DCs, ILCs, NK cells and structural cells regulates inflammatory signaling pathways in the human WAT during obesity (Extended Data Fig. 10).

Discussion
We performed scRNA-seq on a total of 110,250 cells from multiple sorted atlases including CD45− cells, CD45+ cells, macrophages, DCs, NK cells and ILCs. This led to the validation of 13 of 15 previously identified populations, as well as the identification of an additional 15 distinct cell clusters, including previously uncharacterized populations of WAT ILCs, DCs, NK cells and proinflammatory macrophages. Using flow cytometry, we then validated the presence of each of these populations within the human lean and obese WAT using an independent cohort of patients. Finally, we utilized single-cell ligand–receptor analysis to profile both the lean and the obese human WAT interactomes, in addition to a cell type-specific, obesity-enriched signalosome.

Our study identifies a number of unique ILC populations (iNK cells, trNK cells, ILC1s, ILC3s, ILCP-like cells) that have not been described in human WAT previously. We find that the healthy human WAT contains a distinct population of trNK cells that can be differentiated from both WAT mNK and iNK cell populations and shares a similar phenotype with trNK cells described in human liver transplantation studies. Our data suggest that trNK cells as well as ILC1s express IFN-γ, which is implicated in the regulation of obesity-associated transcriptional changes of many cell types, notably as a critical regulator of IM differentiation. Accordingly, previous studies in diet-induced obese mice have suggested that WAT-resident ILC1 and NK populations produce IFN-γ early during the administration of a high-fat diet, and that IFN-γ is important for the regulation of adipose tissue inflammation. As such, trNK cells and ILC1s may play a similar role in the potentiation of human WAT inflammation during obesity, although future studies will be needed to support this conclusion. Our data also suggest that trNK cells are involved in the recruitment of cDC1αs via XCL1/2–XCRI signaling during obesity, similar to mechanisms recently observed within the tumor microenvironment. The full extent of ILC–DC communication in the WAT, and the implications of these interactions, merit attention through future mechanistic studies in mice.

We also identified a subset of human WAT ICL3s that accumulate during obesity. In the lean state, our data suggest that ILC3s may play a homeostatic role, similar to ILC2s. However, in the obese state, our data suggest that ILC3s are mediators of adipose tissue inflammation via expression of LIF, TNFSF13B and MIF. Furthermore, although we were unable to determine the source of IL-17 signaling as suggested by gene set enrichment analysis, our data suggest that adipose ILC3s may contribute to the proinflammatory effects of this cytokine during obesity. As such, our data suggest that resident ILC3s probably play important roles in human WAT biology that were not recognized previously. However, ILC3s are not present in lean or obese mouse WAT, highlighting key differences between mouse and human WAT ILC composition, and suggesting that certain aspects of ILC-mediated inflammation during obesity may not be evolutionarily conserved in mammals.

Our scRNA-seq dataset also identified three unique subpopulations of WAT DCs that accumulate in obese patients. Although the specific
roles of cDC1, cDC2A and cDC2B subsets in mammalian obesity are unknown, studies in mice have implicated WNT signaling and DCs in driving tolerogenic programs in lean WAT\(^6\). Whether this process becomes dysregulated during obesity is unclear. Analysis of the lean interactome suggests that cDC2As serve an immunoregulatory role, similar to DC populations found in tumors\(^5\). During obesity, however, our data suggest that cDC2Bs may contribute to tissue inflammation via expression of MIF, IL-18, IL-1β and TNFSF9. As such, future
studies are necessary to elucidate the roles of these different DCs within the adipose tissue. Similarly, previous studies in diet-induced obese mice have suggested both protective and proinflammatory roles of CD9+ LAMs through TREM2 function or cytokine production, respectively. Our results suggest that human VAT LAMs, alongside IMs, actively produce IL-1β and TNF in obese patients. Both populations may also contribute to adipose tissue inflammation via expression of IL-18, CXCCL8 and PDGFβ. Furthermore, although analysis of endogenous cytokine production suggests that PVMs are not actively producing IL-1β or TNF in obese patients, ligand–receptor analysis suggests that these macrophages may contribute to adipose tissue inflammation via increased chemokine production and recruitment of monocytes into the VAT. These data suggest that there are probably more complex mechanisms underlying the contribution of VAT DCs and macrophages to adipose tissue inflammation and insulin resistance than previously understood.

In summary, our study provides a comprehensive atlas of immune and structural cell populations within the healthy human VAT, offering insight into cell type-specific transcriptional changes and communication networks that underpin obesity-associated VAT inflammation. Our dataset not only increases our understanding of the interactions that occur between cell types in human VAT, but also identifies potential therapeutic targets that may aid in reducing systematic low-grade inflammation in obese patients.

Online content

Any methods, additional references, Nature Research reporting summaries, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41590-021-00922-4.

Received: 14 September 2020; Accepted: 22 March 2021; Published online: 27 April 2021

References

1. Christ, A., Lauterbach, M. & Latz, E. Western diet and the immune system: an inflammatory connection. *Immunity* **51**, 794–811 (2019).
2. Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. *Nature* **576**, 51–60 (2019).
3. Lee, Y. S., Wollam, J. & Olefsky, J. M. An integrated view of immunometabolism. *Cell* **172**, 22–40 (2018).
4. Lackey, D. E. & Olefsky, J. M. Regulation of metabolism by the innate immune system. *Nat. Rev. Endocrinol.* **12**, 15–28 (2016).
5. Pollack, R. M., Donath, M. Y., LeRoith, D. & Leibowitz, G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. *Diabetes Care* **39**, S244–S252 (2016).
6. Ward, Z. J. et al. Projected U.S. state-level prevalence of adult obesity and obesity-related disorders. *Proc. Natl Acad. Sci. USA* **115**, E5096–E5105 (2018).
7. Brown, C. C. et al. Transcriptional basis of human and murine dendritic cell heterogeneity. *Cell* **179**, 846–863.e24 (2019).
8. Kim, J. et al. Silencing CCR2 in macrophages alleviates adipose tissue inflammation and the associated metabolic syndrome in dietary obese mice. *Mol. Ther. Nucleic Acids* **7**, 370 (2015).
9. Kim, J. et al. Selecting CCR2 in macrophages alleviates adipose tissue inflammation and the associated metabolic syndrome in dietary obese mice. *Mol. Ther. Nucleic Acids* **5**, 485–491 (2016).
10. Kim, J. et al. Selecting CCR2 in macrophages alleviates adipose tissue inflammation and the associated metabolic syndrome in dietary obese mice. *Mol. Ther. Nucleic Acids* **7**, 370 (2015).
48. Böttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037. e14 (2018).

49. Macdougall, C. E. et al. Visceral adipose tissue immune homeostasis is regulated by the crosstalk between adipocytes and dendritic cell subsets. Cell Metab. 27, 588–601.e4 (2018).

50. Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257–262 (2020).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature America, Inc. 2021
Methods
Human samples. Human deep subcutaneous WAT samples were obtained from donors undergoing cosmetic abdominoplasty procedures via Barrett Plastic Surgery, Los Angeles. Donor characteristics are summarized in Supplementary Tables 1, 3, 4, and 8. Human samples were defined as healthy status based on no previous history of cardiovascular disease, liver disease, diabetes or immunological disorders, and divided into three categories based on BMI: lean, BMI < 25; overweight, 25 < BMI < 30; obese, BMI ≥ 30. The human samples used in the present study do not qualify as human subjects’ research, confirmed by the UCLA Institutional Review Board. As such, obtaining informed consent was not necessary. Human samples were de-identified and were not obtained for the specific purpose of these studies.

Adipose tissue harvest and cell dissociation. Patient deep subcutaneous adipose tissue was freshly harvested from abdominoplasty samples within an hour of their respective operations. Adipose tissue samples were kept on ice until processing. Adipose tissues were first washed three times with 1X phosphate-buffered saline before physical homogenization in adipose harvest medium ([A/HM] 1X Hank’s balanced salt solution + CaCl₂, + MgCl₂, 5% heat-inactivated fetal bovine serum, 1% l-glutamine, 1% penicillin–streptomycin and 50 μg ml⁻¹ of DNase1) using a blender (900W, Ninja BL450 Series). Homogenized tissue was then distributed into 14-ml round-bottomed tubes and supplemented with collagenase type II digestion (900 W, Ninja BL450 Series). Homogenized tissue was then distributed into approximately 300 million reads per library with 2 × 150 read length. Raw reads were sequenced using the NovaSeq 6000 S2 platform (Illumina) to a depth of 50 read length. Raw reads were aligned to the human genome (hg38) and cells were called using cellranger count (v.3.0.2). Individual samples were aggregated to generate the merged digital library preparation, sequencing and alignment. ScRNA-seq libraries were generated with the Chromium Single Cell 3′ v.3 assay (10X Genomics). Libraries were sequenced using the NovaSeq 6000 S2 platform (Illumina) to a depth of approximately 300 million reads per library with 2 × 50 read length. Raw reads were aligned to the human genome (hg38) and cells were called using cellranger count (v.3.0.2). Individual samples were aggregated to generate the merged digital expression matrix using cellranger allr (v.3.0.2).

Cell clustering and cell-type annotation. The R package Seurat51 (v.3.1.2) was used to cluster the cells into the merged matrix. Cells with <500 transcripts detected or >25% mitochondrial genes were excluded as low quality. The gene counts for each cell were divided by the total gene counts for the cell and multiplied by a scale factor of 10,000, then natural-log transformation was applied to the counts. The FindVariableFeatures function was used to select variable genes with default parameters. The ScaleData function was used to scale and center the counts in the dataset. Principal component analysis was performed on the top 20 principal components. Based on the principal components, 20 principal components were used for cell clustering (resolution = 0.5) and UMAP dimension reduction. The cluster markers were found using the FindAllMarkers function, and cell types were manually annotated based on the cluster markers. Module scores were calculated using the AddModuleScore function with default parameters and used to validate certain cell-type annotations. To calculate the cell composition based on cell type, the number of cells for each cell type from each sample were counted. The counts were then divided by the total number of cells for each sample and scaled to 100% for each cell type.

Cell-type subclustering. Subclustering was performed on all cell types. The same functions described above were used to obtain the subclusters. Subclusters that were exclusively membership by mitochondrial gene expression, indicating low quality, were removed from further analysis. To calculate the composition of lean and obese cells for the subclusters, the numbers of lean and obese cells for each subcluster were counted. The number of lean (or obese) cells in each cluster was then divided by the total number of lean (or obese) cells to calculate the percentages of each cell state. Subclusters were filtered based on >10% frequency for each cell lineage and assigned as a lean- or obese-enriched state if the subcluster contained >5% representation of lean compared with obese cells, and vice versa. Cells with same representation of lean and obese cells were excluded from lean- and obese-specific cell-state analysis. For each cell type, differential expression analysis was carried out on the lean cells from the lean state and obese cells from the obese state. Then IPA was applied to the DEGs to detect the potential upstream regulators driving the differential expression. The upstream regulators that were activated in obese (activation z-score ≥ 2) in at least three cell types were plotted. The normalized expression matrix for ILC and myeloid subtypes was extracted and uploaded to the CytoTRACE webtool (https://cytotrace.stanford.edu/), and the output CytoTRACE score for each cell was then plotted on the UMAP.

Pseudotime trajectory construction. Pseudotime trajectories for ILCs and myeloid cells were constructed using the R package Monocle53 (v.2.10.1). The raw counts for cells in the intended cell types were extracted and normalized by the estimateSizeFactors and estimateDispersions functions with the default parameters. Gene set average expression (HG19) and detected in ≥ 10 cells were retained for further analysis. Variable genes were determined by the differentialGeneTest function with a model against the cell-type identities. The top 2,000 variable genes with the lowest adjusted P value were used to order the cells. The orders were determined by the orderCells function and the trajectory was constructed by the reduceDimension function with default parameters. Differential expression between pseudotime states was carried out using the Seurat function FindMarkers. The DEGs with the lowest adjusted P value were used to plot the heatmap showing the bifurcation expression patterns. RNA-Seq was used to determine the upstream regulators for the DEGs.

Cell–cell ligand–receptor interaction analysis. CellphoneDB (v.2.0.0) was then used to recover the directed dynamic interaction by leveraging RNA-sequencing data. Specifically, the data were first normalized using the velocyto function and then normalized using the graph-function. Finally, the velocities were visualized in the UMAP embedding using the velocity_embedding_stream function. All scVelo functions were used with default parameters.

Cell–ligand–receptor interaction analysis. CellphoneDB (v.2.0.0) was then used to recover the directed dynamic interaction by leveraging RNA-sequencing data. Specifically, the data were first normalized using the velocyto function and then normalized using the graph-function. Finally, the velocities were visualized in the UMAP embedding using the velocity_embedding_stream function. All scVelo functions were used with default parameters.

Analysis with gGOST. Cluster markers from obese-enriched states were input into the functional enrichment analysis query and then analyzed using gGOST functional profiling v.9.9.6 (BD). Cell surface and intracellular staining were performed using the following fluorophore-conjugated antibodies: CD3 (UCHT1), CD19 (L243), CD4 (L202), CD8 (S5/1), IL-1R1 (FAB269A), CD9 (HI9a), IFN-β (B27), CD88 (SS/1), IL-1R1 (FAB269A), CD16 (B16), FCER1A (AER-37 - CRA-1), CD294 (B1M), CD62L (DREG-56), CD49 (AS9), CD301 (H07303), CD196 (CD61E), IL-17A (IL1B), TNF-α, CD11b (M1/70), TCRVα2.2 (3C10), CD8α (RPA-TA), CD61H (3P-5G10), FOXP3 (206D), CD15 (H98), CD4 (RA-T4), CD64 (Y1/82A), CD64 (D10.1), TCRVα2.4–81 (81R1), RO34 (AFK-9s), CD31 (WM59), CD29 (TS2/16) and ICAM-1 (HA58). All antibodies used in this study were validated with human PBMCs before use on human WAT SVF samples.
Human macrophage endogenous cytokine production. Human adipose SVF cells were cultured for 5 h in CR-10 medium containing Brefeldin A (1:1,000; BioLegend) and monensin (2 μM; BioLegend) and then analyzed for intracellular cytokine production via flow cytometry. Cells were cultured in medium alone as a negative control.

Ex vivo stimulation of human ILCs. Human adipose SVF cells were cultured for 5 h in CR-10 medium containing Brefeldin A (1:1,000; BioLegend) and monensin (2 μM; BioLegend) with or without phorbol 12-myristate 13-acetate (Sigma) and ionomycin (Sigma). For quantification of IL-17A staining, SVF cells were cultured overnight in CR-10 and then subsequently stimulated in the presence of phorbol 12-myristate 13-acetate, ionomycin, Brefeldin A and monensin for 5 h.

Quantification, statistical analysis and reproducibility. For graphs, data are shown as mean ± s.e.m. and, unless otherwise indicated, statistical differences were evaluated using a Student’s t-test with Welch’s correction to assume a non-normal variance in our data distribution. For cell-type density analysis, linear regression was performed alongside two-tailed Pearson’s correlation analysis with 95% confidence intervals (CIs). P < 0.05 was considered significant. The scRNA-seq of sorted CD45+ and CD45− cells was performed initially. This was followed by scRNA-seq of sorted macrophage, DC, ILC and NK cell populations. Flow cytometric analysis of each patient was performed independently. Graphs were produced and statistical analyses were performed using GraphPad Prism.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
The scRNA-seq datasets are accessible from the Gene Expression Omnibus with accession nos. GSE155960 and GSE156110.

References
51. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
52. Koay, H.-E. et al. A divergent transcriptional landscape underpins the development and functional branching of MAIT cells. Sci. Immunol. 4, eaay6039 (2019).
53. Szabo, P. A. et al. Single-cell transcriptomics of human T cells reveals tissue activation signatures in health and disease. Nat. Commun. 10, 4706 (2019).
54. Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
55. Wong, K. L. et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118, e16–e31 (2011).
56. Trappnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).
57. Bergen, V., Lange, M., Peidli, S., Wolf, F. A. & Theis, F. J. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat. Biotechnol. https://doi.org/10.1038/s41587-020-0591-3 (2020).
58. Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191–W198 (2019).

Acknowledgements
We thank members of the following labs for helpful discussions: A. Freud, T.E.O., M.P. and M. Su. We thank D. Barrett for discarded surgical subcutaneous adipose tissue samples. We thank R. Modlin for assistance with IPA. A.D.H was supported by the Ruth L. Kirschstein National Research Service (award no. AI007323). T.E.O. was supported by the National Institutes of Health (grant nos. F30DK063491 and AI145997). F.M. was supported by the Whitcome Fellowship at UCLA.

Author contributions
A.D.H. and T.E.O. designed the study. F.M. and M.P. performed scRNA-seq bioinformatics. A.D.H, YY.W. and R.S. performed all other experiments. A.D.H. and T.E.O. wrote the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41590-021-00922-4.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41590-021-00922-4.

Correspondence and requests for materials should be addressed to T.E.O.

Peer review information Nature Immunology thanks Jorge Moscat, Sarah Teichmann, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Zoltan Fehervari was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | See next page for caption.
Extended Data Fig. 1 | Lineage-associated gene signatures of CD45+ and CD45– SVF cells from healthy human WAT. a, Dot plot showing selected top differentially expressed marker genes for each cluster, supporting assignment of clusters to compartments shown in Fig. 1b. Color saturation indicates the strength of expression in positive cells, while dot size reflects the percentage of each cell cluster expressing the gene. b, Violin plots showing expression levels of additional cluster markers for the indicated structural cell populations. c, Representative gating strategy for scRNAseq-defined human WAT non-immune cell populations (CD45–): Endothelial cell: CD31+, Smooth muscle cell (SMC): CD31–CD34–CD29+, Adipocyte precursor cell (APC): CD31–CD34+CD29+, Preadipocyte: CD31–CD34+CD29+ICAM-1–CD26+, Interstitial progenitor cell: CD31–CD34–ICAM-1+CD29+ICAM-1+CD26+. d, Density correlation analysis of the indicated non-immune subsets with patient BMI. Line of best fit and 95% confidence intervals are shown for each plot. Each point represents an individual patient. Linear regression and two-tailed Pearson Correlation analysis with 95% confidence intervals were conducted. p < 0.05 was considered significant.
Extended Data Fig. 2 | Single cell analysis reveals heterogeneous adaptive lymphocyte populations in healthy human WAT. **a,** UMAP plot of 36,601 subclustered human adipose effector lymphocytes from Fig. 1. Cluster analysis yields 9 distinct clusters comprising of T cell subsets, ILCs and NK cells.

**b,** Unbiased heatmap of gene expression of the top 6 unique cluster marker genes for each T cell cluster. Cluster identities are shown above the heatmap. Color saturation indicates the strength of expression.

**c,** Violin plots showing RNA expression of additional cluster markers for the indicated T cell populations.

**d,** Representative gating strategy for scRNAseq-defined human WAT T cell populations (CD45+Lin− (CD34+CD19+CD14+): γδ T cell (γδ T); TCRγδ+Va24-Jα18+Vα7.2+, NKT cell (NKT): TCRγδ+Va24-Jα18+Vα7.2+, MAIT cell (MAIT): TCRγδ+Va24-Jα18+Vα7.2+TCRαβ+, CD8+ T cell (CD8 T): TCRγδ−Va24-Jα18+Vα7.2+TCRαβ+CD8α+CD4−, CD8α+CD4+ T cell (CD8α+CD4+): TCRγδ+Va24-Jα18+Vα7.2+TCRαβ+CD8α+CD4+FoxP3+, Regulatory T cell (Treg): TCRγδ+Va24-Jα18+Vα7.2+TCRαβ+CD8α+CD4+FoxP3+). e, Representative histogram of KLRB1 (CD161) expression on human WAT T cell subsets. f, Representative flow cytometry plot of CD8α and CD4 expression on human WAT γδ T cells.

e,f, Data is representative of 4 individual patient samples.

**g,** Density correlation analysis of the indicated T cell subsets with patient BMI. Line of best fit and 95% confidence intervals are shown for each plot. Each point represents an individual patient. Linear regression and two-tailed Pearson Correlation analysis with 95% confidence intervals were conducted. p < 0.05 was considered significant.
Extended Data Fig. 3 | Single cell analysis identifies unique human WAT-resident ILCs. 

a, Representative sorting strategy for Lin−CD7+ cell populations based on expression of CD200R1; used in Fig. 2. 

b, Unsupervised heatmap of the top 5 differentially expressed cluster marker genes for each indicated innate lymphoid cell cluster. Cluster identities are shown above the heatmap. Color saturation indicates the strength of expression. 

c, Selected UMAP feature plots showing RNA expression of additional cluster markers, based on the UMAP shown in Fig. 2a. 

d, UMAP of sorted innate lymphoid cell populations denoted by the source of the sorted sample (CD200R1+ vs CD200R1−) and patient source classification as lean (red, green) or obese (blue, purple); based on the UMAP shown in Fig. 2a. 

e, Bar plots showing the proportion of innate lymphoid cells derived from 7 lean (blue) and 5 obese (red) patients.
Extended Data Fig. 4 | Flow cytometry analysis of scRNAseq-identified human WAT ILCs. 

**a, b,** Representative gating strategies for the scRNAseq-defined human WAT (a) NK cell and (b) ILC populations identified in Fig. 2. Human WAT ILC populations are defined as CD45^+Lin^- (CD3^+TCRαβ^+CD19^+CD34^+CD14^-CD5^-TCRγδ^-EOMES^-CD7^-CD200R^+)); ILC1: TBET^+, ILC2: TBET^+CRTH2^-NKp44^+, ILC3: TBET^-CRTH2^-NKp44^+, ILCP-like: TBET^-CRTH2^-NKp44^-CD62L^-^+. **c,** Representative histogram of IFN-γ by human WAT NK cell subsets. Unstim refers to CD200R^- cells cultured without PMA and Ionomycin. **d,** Representative histograms of TBET, CRTH2, NKp44, and RORC expression on human WAT ILC subsets. **e,** Analysis of RORC MFI values from human WAT ILC subsets. Each point represents an individual patient (n = 3). ILCP-like: p = 0.0198, ILC1: p = 0.0313, ILC2: p = 0.0194. **f,** Representative flow cytometry plots of CD7^-CD200R^+ cells isolated from human PBMC. **g,** Density correlation analysis of ILC2 with patient BMI. Each point represents an individual patient. **h, i,** Density of indicated ILCs by BMI classification. Each point represents an individual patient; (h) n = 8 lean and n = 7 obese patients, (i) ILC1: n = 10 lean and n = 7 obese patients; ILC2, ILC3, ILCP-like: n = 5 lean and n = 3 obese patients. ILC2: p = 0.0293, ILC3: p = 0.0094, ILCP-like: p = 0.022. Data is representative of 3 individual patient samples. Samples were compared using two-tailed Student’s t-test with Welch’s correction, assuming unequal SD, and data are presented as individual points with the mean ± SEM (*p < 0.05, **p < 0.01). Linear regression and two-tailed Pearson Correlation analysis with 95% confidence intervals were conducted. p < 0.05 was considered significant.
Extended Data Fig. 5 | Analysis of ILC1 and ILC3 fate DEGs suggests a clear developmental bifurcation. Bifurcation heatmap of enriched genes for ILC1 (left), ILCP-like (middle) and ILC3 (right). Color indicates increased (red) or decreased (blue) expression.
Extended Data Fig. 6 | Single cell analysis identifies unique myeloid populations within healthy human WAT. a, Representative sorting strategies for CD11b+CD14+ macrophage and HLA-DR+CD11c+ dendritic cell populations indicated in Fig. 4. b, Heatmap shows the top 4 differentially expressed cluster marker genes for each indicated myeloid cell cluster. Cluster identities are shown above the heatmap. Color saturation indicates the strength of expression.

c,d, Violin plots showing RNA expression levels of cluster markers for (c) myeloid (d) and monocyte populations.

e, Classical, Intermediate, and Nonclassical Monocyte gene module score analysis for the indicated monocyte populations based on comparison of signature genes for each cell type from previously defined datasets to DEGs within each cluster.

f, Neutrophil gene module score analysis for the indicated myeloid populations based on comparison of signature genes for each cell type from previously defined datasets to DEGs within each cluster.

g, Bar plots showing the proportion of myeloid cells derived from 7 lean (blue) and 5 obese (red) patients.
Extended Data Fig. 7 | Flow cytometry analysis of scRNAseq-identified human WAT macrophage and dendritic cell populations. a, Representative gating strategy for scRNAseq-defined human WAT macrophage and DC populations identified in Fig. 4. b, Representative histograms of CD64, CD68, CD88, and CD15 expression on human WAT macrophage cell subsets, CD14+ monocytes and CD15+ neutrophils isolated from human PBMC. c, Flow cytometry analysis of endogenous TNF-α production by human WAT macrophage subsets from n = 4 lean, n = 2 overweight, and n = 4 obese patients. Each point represents an individual patient. d, Representative flow cytometry histograms of CLEC10A and FCER1A expression on human WAT DC subsets. e, Density of the indicated DC populations by BMI classification, n = 9 lean and n = 7 obese patients. Each point represents an individual patient. f, Representative flow cytometry plots of human WAT macrophage populations from lean (left) and obese (right) patients. g, Density of the indicated macrophage populations by BMI classification, n = 7 lean and n = 7 obese patients. Each point represents an individual patient. b,d, Data is representative of 3 individual patient samples. Samples were compared using two-tailed Student’s t test with Welch’s correction, assuming unequal SD, and data are presented as individual points with the mean ± SEM (*p < 0.05, **p < 0.01).
Extended Data Fig. 8 | Analysis of the DEGs between PVM and IM fates shows a clear bifurcation in gene expression programs. Bifurcation heatmap of enriched genes for PVM (left), Mo-1 (middle) and IM (right). Color indicates increased (red) or decreased (blue) expression.
Extended Data Fig. 9 | Novel human WAT cell types contribute to obesity-associated inflammatory networks. a, Dot plots showing expression of ligands (left) and receptors (right) in novel human WAT cells; only ligands and receptors from cell types with detected expression (>25%) are shown. Implicated chemokines can be found in the lower panel. Color saturation indicates the strength of expression in positive cells, while dot size reflects the percentage of each cell cluster expressing the gene. b–e, GOST analysis of obese-enriched differentially expressed genes for the indicated novel human WAT cell types. Terms were considered statistically significantly enriched if -log_{10}(P_{adj})<0.05.
Extended Data Fig. 10 | Proposed model of cell-cell interactions in healthy lean and obese human WAT. In lean WAT, IL-15 expression from cDC2A coupled with IL-15RA expression from APCs may support the viability of IL-15RB-expressing ILCs and NK cell populations. CSF1 (M-CSF) expression from APCs and IL-13 from ILC2s likely drives the Mo-1 transition to PVMs, while CSF2 from APCs may support dendritic cell homeostasis. cDC2A-derived CD200 could suppress ILC activation at steady-state. TGFβ, PDGF, AREG, and GAS6 signaling from dendritic cells and PVM to APCs may promote tissue homeostasis. During obesity, IL-23 from an unknown source could drive the differentiation and accumulation of WAT ILC3s from ILCP-like cells. cDC2B-derived IL-18 and potentially IL-12 might stimulate the production of IFNγ by trNK and ILC1 subsets and contribute to the development of LAM from PVM. Increased CCL2 production from hypoxia-sensing PVM and SMC could recruit circulating Mo-1 into the WAT where MIF, LIF, and IFN-γ signaling from ILCs and NKs, as well as IL-1β, OSM and TNF-α signaling from IM, LAM, and cDC2B could polarize Mo-1 to the IM fate. trNK production of TNF5F14 (LIGHT) may further promote activation of cDC2B and IM. Together, these interactions suggest a cell type specific positive feedback loop whereby accumulation and polarization of WAT-resident lymphoid and myeloid cell types potentiate inflammation during human obesity.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

confirmed

☐ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐ The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
☐ A description of all covariates tested
☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☐ Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection Flow Cytometry: Attune NXT Software v3.1.2

Data analysis

Sequencing Analysis:
Raw reads were aligned to human genome (hg18) and cells were called using cellranger count (v3.0.2). Individual samples were aggregated to generate the merged digital expression matrix using cellranger aggr (v3.0.2). The R package Seurat (v3.1.2) (Butler A. et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 36(5):411-420, 2018) was used to cluster the cells in the merged matrix.

CellPhoneDB (v2.0.0) [Efremova M. et al. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc. 15(4):1484-1506, 2020] was applied for ligand receptor analysis.

Pseudo-time trajectories were constructed using the R package Monocle (v2.10.1) [Trapnell C, Cacchiarelli D, Grimsby J, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 32(4):381-386, 2014].

velocyto [La Manno G. et al. RNA velocity of single cells. Nature. 560(7719):494-498, 2018] was used to distinguish unspliced and spliced mRNAs in each sample. The python package scVelo [Bergen V. et al. Generalizing RNA velocity to transient cell states through dynamical modeling (published online ahead of print, 2020 Aug 3). Nat Biotechnol. 10.1038/s41587-020-0591-3, 2020] was then used to recover the directed dynamic information by leveraging the splicing information. Ingenuity pathway analysis was applied to the DEGs to determine the potential upstream regulators driving the differential expression. The upstream regulators that were activated in obese (activation z score >= 2) in at least three cell types were plotted. The normalized expression matrix for ILC and myeloid subtypes were extracted and uploaded to the CytoTRACE webtool (https://cytotrace.stanford.edu/), and the output CytoTRACE score for each cell was then plotted on the UMAP.

gGOSI Analysis:
DEGs from obese-enriched states were input into the functional enrichment analysis query and then analyzed using gGOSI functional profiling (Raudvere, U. et al. g2Profiler: a web server for functional enrichment analysis and conversions of gene lists [2019 update]. Nucleic Acids Research 47, W191–W198, 2019).
Flow Cytometry and Patient Data Analysis:
Flow cytometry quantification was performed using FlowJo v9.9.6 (https://www.flowjo.com/solutions/flowjo).
Statistical analysis was performed using GraphPad Prism v7.0c (https://www.graphpad.com/scientific-software/prism).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The single cell RNA sequencing datasets are accessible from GEO with accession number GSE155960 and GSE156110.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences  ☐ Behavioural & social sciences  ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-list.pdf.

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size
No statistical methods were used to predetermine the sample size. As many patients as possible were included for each group, with a minimum of 3 patients per group in order to determine statistical significance where applicable.

Data exclusions
Patient samples were only included in our study if they were defined as "healthy," based on no prior history of cardiovascular disease, liver disease, diabetes or immunological disorders.

Replication
The results obtained from our scRNA-seq dataset were validated using both of the methods listed below:
1) Single-cell RNA sequencing validation using independent FACS sorted SVF samples derived from an additional patient cohort. scRNAseq of sorted CD4+ and CD4- cells was performed initially. This was followed by scRNAseq of sorted Macrophage, DC, ILC, and NK cell populations.
2) Cellular phenotyping by flow cytometry of additional tissue samples [SVF] from an additional patient cohort. Analysis of each patient was performed independently.

Randomization
Human deep subcutaneous white adipose tissue samples were obtained from donors undergoing cosmetic abdominoplasty procedures and were collected consecutively and then allocated into three groups based on body mass index (BMI): lean: BMI < 25; overweight: 25 < BMI < 30; obese: BMI > 30.

Blinding
BMI classification was blinded during sample processing, data collection, and generation (flow cytometry), as well as initial analysis of the scRNA-seq data, which included filtration and clustering.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| ☒   | Antibodies            |
| ☒   | Eukaryotic cell lines |
| ☒   | Palaeontology and archaeology |
| ☒   | Animals and other organisms |
| ☒   | Human research participants |
| ☒   | Clinical data         |
| ☒   | Dual use research of concern |

Methods

| n/a | Involved in the study |
|-----|-----------------------|
| ☒   | ChiP-seq              |
| ☒   | Flow cytometry        |
| ☒   | MRI-based neuroimaging |
**Antibodies**

**Antibodies used:**
- CD3 FITC eBioscience UCHT1 1:400 Cat#11-0038-42
- TCRab FITC eBioscience IP26 1:800 Cat#11-9986-42
- CD26 PE eBioscience 2A6 1:200 Cat#12-0269-42
- CD56 APC eBioscience TULY56 1:40 Cat#17-0566-41
- CD1c PE/Cyanine7 eBioscience L161 1:600 Cat#25-0015-42
- CD19 FITC eBioscience SJ55-C1 1:100 Cat#MHCD1901
- CD34 FITC eBioscience 581 1:200 Cat#CD34-581-01
- CD14 FITC eBioscience TuK4 1:40 Cat#MHCD1401
- CD7 Alexa Fluor 700 eBioscience 124-1D1 1:100 Cat#56-0079-42
- CD45 PerCP-Cyanine5.5 eBioscience H300 1:100 Cat#45-0459-42
- T-Bet PE/Cyanine7 eBioscience 4B10 1:200 Cat#644810
- CD5 FITC eBioscience UCHT1 1:40 Cat#11-0059-42
- CD7 FITC eBioscience 124-1D1 1:100 Cat#11-0079-42
- TCRgd FITC eBioscience B1.1 1:100 Cat#11-9959-42
- CD14 APC eBioscience TuK4 1:40 Cat#MHCD1405
- Perforin Pacific Blue BioLegend B-D48 1:400 Cat#353305
- CD20DR PE/Cyanine7 BioLegend Ox10 1:100 Cat#329312
- EOMES eFluor 660 eBioscience WD192 1:50 Cat#50-4877-42
- CD11c APC/eFluor 780 eBioscience B125 3:40 Cat#47-0128-42
- HLA-DR Brilliant Violet 510 BioLegend L249 1:50 Cat#307646
- CD20e Brilliant Violet 421 BioLegend 15-2 1:40 Cat#321126
- IL-13 Brilliant Violet 421 BioLegend JES51-542 1:100 Cat#501915
- CD9 PE BioLegend H9a 1:500 Cat#212105
- IFN-g APC/Cyanine7 BioLegend B27 1:100 Cat#506523
- CD88 PE BioLegend 55/1 1:400 Cat#344303
- IL-1R1 APC/R&D Systems FAB269A 1:100 Cat#FAB269A-025
- IL-2 Pacific Blue BioLegend M21-17H12 1:100 Cat#500324
- EOMES FITC eBioscience WD192 1:50 Cat#11-4877-42
- CD16 FITC eBioscience C16 1:400 Cat#11-0068-41
- CD88 FITC BioLegend 55/1 1:400 Cat#344305
- FCER1A PE BioLegend AER-37 (CRA-1) 1:40 Cat#336409
- CD294 Pacific Blue BioLegend BM16 1:40 Cat#350130
- CD62L PerCP-Cyanine5.5 BioLegend DREG-56 1:40 Cat#304824
- CD45 Brilliant Violet 510 BioLegend H130 1:100 Cat#304036
- CD89 FITC BioLegend A59 1:400 Cat#354113
- CD26 PerCP-Cyanine5.5 BioLegend B5A5 1:100 Cat#302715
- CD301 PE BioLegend H037G3 1:40 Cat#354703
- CD196 APC/Cyanine7 BioLegend G043E1 1:100 Cat#353431
- CD16 APC/eFluor 780 eBioscience CB16 1:400 Cat#47-0168-42
- IL-17A Pacific Blue BioLegend B1L6B 1:100 Cat#312311
- TNF-a PE/Cyanine7 BioLegend Mab11 1:100 Cat#502929
- IL-1b PE eBioscience CRM56 1:100 Cat#12-7018-41
- CD1c FITC eBioscience L161 1:600 Cat#11-0015-42
- CD294 PerCP-Cyanine5.5 BioLegend BM16 1:40 Cat#350115
- CD62L APC/Cyanine7 BioLegend DREG-56 1:40 Cat#304813
- CD336 APC Miltenyi Biotec 2.29 1:40 Cat#130-120-623
- CD12b Alexa Fluor 700 BioLegend M/170 1:200 Cat#K101222
- TCR Vα7.2 PerCP-Cyanine5.5 BioLegend 3C10 1:50 Cat#351709
- CD8α Pacific Blue BioLegend RPA-TB 1:100 Cat#301026
- CD161 APC BioLegend HP-3G10 1:50 Cat#339911
- FOXP3 PE BioLegend 206D 1:50 Cat#320107
- CD15 PE/Cyanine7 BioLegend H98 1:100 Cat#301923
- TCRab Alexa Fluor 700 BioLegend IP26 1:100 Cat#300729
- CD4 APC/Cyanine7 BioLegend RPA-T4 1:100 Cat#300517
- TCRgd PE/Cyanine7 BioLegend B1 1:50 Cat#331221
- CD68 PE BioLegend Y1/B2A 1:40 Cat#338087
- CD64 PE/Cyanine7 BioLegend 10.1 1:100 Cat#305021
- TCR Vα24-Jα18 APC BioLegend 6B11 1:50 Cat#342907
- RORC APC eBioscience AFK-5 1:40 Cat#17-6988-80
- CD31 APC/Cyanine7 BioLegend WS59 1:100 Cat#303119
- CD29 PerCP-Cyanine5.5 BioLegend TS2/16 1:100 Cat#303023
- ICAM-1 Alexa Fluor 700 BioLegend H58 1:100 Cat#353125

**Validation**

All antibodies used in this study were validated in our own hands on human PBMCs prior to use on human WAT SVF samples.

---

**Human research participants**

Policy information about [studies involving human research participants](#)

**Population characteristics**

Human deep subcutaneous white adipose tissue samples were obtained from donors undergoing cosmetic abdominoplasty.
Flow Cytometry

Plots

Confirm that:
- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Cells were isolated from the human WAT as described in the methods section. After isolation of the SVF, cells were analyzed for cell-surface markers using fluorochrome-conjugated antibodies. Cell surface staining was performed in 1X PBS and intracellular staining was performed using the eBioscience Foxp3/Transcription Factor or BD Cytofix/Cytperm kits. Cells were stained for 30 minutes and then analyzed by flow cytometry or sorted as described. Compensation was performed using unstained cellular controls.

Instrument

Attune NxT Acoustic Focusing Cytometer, BD FACSAria III

Software

Attune NxT Software v3.1.2, with quantification performed using FlowJo v9.9.6

Cell population abundance

Non-immune cells (CD45-) and immune cells (CD45+) comprised approximately 31.9% and 53.6% of the parent gate, respectively (gated on FSC, SSC, and singlets).

Macrophages comprised approximately 25.5% of CD45+ cells in lean samples and 38.9% of CD45+ cells in obese samples. Dendritic cells comprised approximately 0.92% of CD45+ cells in lean samples and 1.47% of CD45+ cells in obese samples. ILC3 comprised approximately 0.29% of CD45+ cells in lean samples and 0.31% of CD45+ cells in obese samples. NK cells comprised approximately 3.40% of CD45+ cells in lean samples and 3.40% of CD45+ cells in obese samples. Purity was greater than 95% for each population as assessed by flow cytometry.

Gating strategy

Cells were gated first based on size using forward and side scatter, followed by identification of singlets using FSC-H and FSC-A.

We then gated as follows for the sorted populations:

- Non-immune cells (CD45-);
- Immune cells (CD45+);
- Macrophages (CD45+Lin-CD3-TCRβ-CD19-CD34-CD5-CD7-CD11b+CD14+);
- Conventional dendritic cells (CD45+Lin-CD3-TCRβ-CD19-CD34-CD5-CD7-CD11b-CD14int-CD8α-CD64+), NK cells (CD45+Lin-CD3-TCRβ+CD19-CD34-CD5-CD7-CD122+), ILC3 (CD45+Lin-CD3-TCRβ+CD19-CD34-CD4-CD5-CD7+CD200R-), and LAG3 (CD45+Lin-CD3-TCRβ+CD19-CD34-CD4-CD5-CD7+CD200R+).

We gated as follows for validation of these populations by flow cytometry:

- WAT non-immune populations: (CD45-): Endothelial cell: CD31+, Smooth muscle cell (SMC): CD31-CD34-CD29-, Adipocyte precursor cell (APC): CD31-CD34-CD29+, Predisaposocyte: CD31-CD34+CD29intCAM-1+CD26-, Interstitial progenitor cell: CD31-CD34+CD29intCAM-1+CD26+.

T cell populations (CD45+Lin-CD34-CD19-CD14-); y6 T cell: TCRβ-VE-24-Ja18+, NKT cell: TCRβ-VE-24-Ja18+, MALT cell: TCRβ-VE-24-Ja18+Jα182+CD38+, CD8+ T cell: TCRβ-VE-24-Ja18+Jα182+CD38+CD8α+, CD4+ T cell: TCRβ-VE-24-Ja18+Jα182+CD38+CD8α-CD4+.

We gated as follows for validation of these populations by flow cytometry:

WAT ILC populations (CD45+Lin-CD3-TCRβ+CD19-CD34-CD5-CD7+CD200R+): ILC1: CD3+ TCRβ+, ILC2: CD25+ TCRβ+, ILC3: CD25+ TCRβ-.

- WAT macrophage populations (CD45+Lin-CD3-TCRβ+CD19-CD34-CD5-CD7+CD200R+); ILC1: CD3+ TCRβ+, ILC2: CD25+ TCRβ-.

- WAT dendritic cell populations (CD45+Lin-CD3-TCRβ+CD19-CD34-CD5-CD7+CD200R+); ILC1: CD3+ TCRβ-.

- WAT conventional type 1 dendritic cell (DC1): CD1c-CD26+, conventional type 2 dendritic cell A (DC2A): CD1c+CD26-CD103+CD11c+.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary information.